VHIR Annual Report 201

Vall d'Hebron. Institut de Recerca

Diabetes, Metabolism

Rafael Simó Canonge


The Diabetes and Metabolism Research Group has been recognized as a consolidated group by the Generalitat de Catalunya, as well as a group of excellence by the ANEP. Apart from belonging to CIBERDEM, our group is associated with the cardiovascular diseases network (RECAVA). Our research is mainly addressed to the pathophysiology of diabetic retinopathy and obesity with the final goal of discovering new therapeutic targets. Our combination of basic and clinical research is important not also in obtaining relevant results, but also in facilitating the rapid transference of these results to clinical practice. At present our group is coordinating a European Project (EUROCONDOR) funded by EC (HEALTH-2011). The main aim of this project (in which are involved 18 partners from 8 countries) is to examine the safety and effectiveness of neuroprotective drugs topically administered for preventing or arresting the development of diabetic retinopathy”

Research lines

  • Physiopathology of diabetic retinopathy.
  • Insulin resistance and obesity: new pathogenic candidates and the study of co-morbidities.
  • Endothelial dysfunction, dyslipideamia and cardiovascular disease in type 2 diabetes.
  • Non-invasive monitorization of blood glucose.

[view all the research lines]


Total: 14

Impact Factor: 51.593

avg. impact factor: 3.685

Selected articles

Hernandez C, Candell-Riera J, Ciudin A, Francisco G, Aguade-Bruix S, Simo R.
Prevalence and risk factors accounting for true silent myocardial ischemia: a pilot case-control study comparing type 2 diabetic with non-diabetic control subjects
Diabetol. 2011 Jan 21;10(1):9.
IF: 2.720

Lecube A, Sampol G, Muñoz X, Ferrer R, Hernandez C, Simo R.
TNF-alpha system and lung function impairment in obesity
Cytokine. 2011 May;54(2):121-4.
IF: 3.537

Villarroel M, Garcia Ramirez M, Corraliza L, Hernandez C, Simo R.
Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1beta by suppressing AMP-activated protein kinase (AMPK) activation
Diabetologia. 2011 Jun;54(6):1543-53.
IF: 6.973

Garcia Ramirez M, Hernandez C, Ruiz Meana M, Villarroel M, Corraliza L, Garcia Dorado D, Simo R.
Erythropoietin protects retinal pigment epithelial cells against the increase of  permeability induced by diabetic conditions: Essential role of JAK2/ PI3K signaling
Cell Signal. 2011 Oct;23(10):1596-602.
IF: 4.243

Lecube A, Pachon G, Petriz J, Hernandez C, Simo R.
Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement
PLoS One. 2011;6(8):e23366.
IF: 4.411

R. Pardo, N. Enguix, J. Lasheras, J.E. Feliu, A. Kralli, J.A. Villena (2011).
Rosiglitazone-induced mitochondrial biogenesis in white adipose tissue is independent of peroxisome proliferator-activated receptor-gamma coactivator-1alpha
PLoS One 6(11): e26989.
IF: 4.092

[view all the articles]

expand list

Main research projects

PI: Simó Canonge, Rafael
Neurodegeneración en la patogénesis de la retinopatía diabética incipiente. Estudio de los mecanismos impllicados a través de un abordaje integrado de biología de sistemas

PI: Hernández Pascual, Cristina
Depósito de glucógeno en la retina y neurodegeneración: un nuevo mecanismo implicado en la patogénesis de la retinopatía diabética

PI: Simó Canonge, Rafael
Neurodegeneration as an early eent in the pathogenesis of diabetic netinopathy. Study of involved mechanisms and new therapeutic strategies

PI: Simó Canonge, Rafael
Neurodegeneration as an early eent in the pathogenesis of diabetic netinopathy. Study of involved mechanisms and new therapeutic strategies

PI: Villena, Josep
Role of thePGC-1beta coactivator in white adipose tissue and its contribution to the development of obesity and type 2 diabetes

[view all the research projects]

expand list


Application Form No: ES P200702179

expand list